{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:37:53Z","timestamp":1792715873528,"version":"4.5.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010463","name":"Institut Curie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010463","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100024218","name":"ARCAGY-GINECO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024218","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.esmoop.2026.108585","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:26:56Z","timestamp":1790699216000},"page":"108585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of pembrolizumab\u2013lenvatinib in metastatic endometrial cancer: results from the French multicenter early access program"],"prefix":"10.1016","volume":"11","author":[{"given":"D.","family":"Bello Roufai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mansi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.H.","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-D.","family":"Fumet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kalbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Airoldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3842-7168","authenticated-orcid":false,"given":"F.","family":"Cherifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Hanvic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Auvray-Kuentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Billemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gervais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Batti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6338-9306","authenticated-orcid":false,"given":"S.","family":"Quesada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Betrian-Lagarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-C.","family":"Hardy-Bessard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Vegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Prulhiere-Corviole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Muzellec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2111-4166","authenticated-orcid":false,"given":"P.","family":"Bouchaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8832-2562","authenticated-orcid":false,"given":"P.","family":"Corbaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Chaix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Collot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Garbay-Decoopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9338-0345","authenticated-orcid":false,"given":"M.-A.","family":"Benderra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2806-413X","authenticated-orcid":false,"given":"M.","family":"Kfoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Augereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.esmoop.2026.108585_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4708","article-title":"Estimated projection of US cancer incidence and death to 2040","volume":"4","author":"Rahib","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108585_bib3","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1055-9965.EPI-04-0871","article-title":"Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention","volume":"14","author":"Bray","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108585_bib4","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.3390\/ijerph19073789","article-title":"Incidence and trend of type I and II endometrial cancer in women from two population-based European cancer registries (1998\u20132012)","volume":"19","author":"Rodr\u00edguez-Palacios","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108585_bib5","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/ijgc-2021-002444","article-title":"Trends over time in the incidence and use of hormonal therapy in endometrial cancer: a population-based study in the Netherlands","volume":"31","author":"Van Weelden","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"23","key":"10.1016\/j.esmoop.2026.108585_bib6","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.esmoop.2026.108585_bib7","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108585_bib8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108585_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013713","article-title":"Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 study 309\/KEYNOTE-775","volume":"14","author":"Makker","year":"2026","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.esmoop.2026.108585_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1404669","article-title":"Efficacy and safety of lenvatinib plus pembrolizumab in patients with advanced and recurrent endometrial cancer: a systematic review and meta-analysis","volume":"15","author":"Yan","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.esmoop.2026.108585_bib11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ygyno.2025.08.008","article-title":"Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability","volume":"201","author":"Corr","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108585_bib12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygyno.2021.04.034","article-title":"Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer","volume":"162","author":"How","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.esmoop.2026.108585_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2024.10.008","article-title":"Real world outcomes in patients with recurrent, advanced, or metastatic endometrial cancer treated with lenvatinib plus pembrolizumab","volume":"37","author":"Pawsey","year":"2025","journal-title":"Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108585_bib14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2025.03.034","article-title":"Reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer","volume":"196","author":"Ta","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108585_bib15","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1200\/JCO-24-01326","article-title":"First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: a randomized, open-label, phase III trial","volume":"43","author":"Marth","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108585_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102124","article-title":"Checkpoint inhibitor rechallenge in advanced endometrial cancer: revisiting the immune landscape beyond first-line therapy","volume":"35","author":"Podder","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108585_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004233","article-title":"Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer","volume":"10","author":"Lheureux","year":"2022","journal-title":"J Immunother Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926025305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926025305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:42:31Z","timestamp":1792712551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926025305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2059702926025305"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108585","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of pembrolizumab\u2013lenvatinib in metastatic endometrial cancer: results from the French multicenter early access program","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108585","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108585"}}